What is he best known for?
The fields of study he is best known for:
- Immune system
- Gene
- Cancer
Tuna Mutis mostly deals with Immunology, Cytotoxic T cell, Daratumumab, Isatuximab and Minor histocompatibility antigen.
While working in this field, Tuna Mutis studies both Immunology and Pepsin.
His study looks at the intersection of Cytotoxic T cell and topics like CD8 with Stem cell and Major histocompatibility complex.
His Daratumumab research incorporates elements of Bone marrow and CD38.
He interconnects Cancer research and SLAMF7 in the investigation of issues within Isatuximab.
The study incorporates disciplines such as Complement-dependent cytotoxicity and Immunotherapy in addition to Cancer research.
His most cited work include:
- Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors (623 citations)
- Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma (393 citations)
- Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. (393 citations)
What are the main themes of his work throughout his whole career to date?
Tuna Mutis spends much of his time researching Immunology, Cancer research, Multiple myeloma, Cytotoxic T cell and Antigen.
Tuna Mutis combines subjects such as Stem cell and Transplantation with his study of Immunology.
His Cancer research research includes themes of Ex vivo, Cell culture, Bone marrow and Antibody, Monoclonal antibody.
Tuna Mutis has researched Cytotoxic T cell in several fields, including T cell, CD8 and Molecular biology.
His study focuses on the intersection of Antigen and fields such as Antigen presentation with connections in the field of CTL*.
Tuna Mutis focuses mostly in the field of Daratumumab, narrowing it down to matters related to CD38 and, in some cases, Retinoic acid.
He most often published in these fields:
- Immunology (50.00%)
- Cancer research (40.40%)
- Multiple myeloma (33.33%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (40.40%)
- Multiple myeloma (33.33%)
- Immunotherapy (25.76%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, Multiple myeloma, Immunotherapy, Antibody and Daratumumab.
The Cancer research study combines topics in areas such as Cell culture, Antigen, Bone marrow, CD38 and Monoclonal antibody.
His Bone marrow study incorporates themes from Retinoic acid and In vivo.
His Immunotherapy study integrates concerns from other disciplines, such as Bispecific antibody and Combination therapy.
His research investigates the connection with Antibody and areas like Chronic lymphocytic leukemia which intersect with concerns in B cell.
His Daratumumab study is related to the wider topic of Immunology.
Between 2017 and 2021, his most popular works were:
- High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action (51 citations)
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells (41 citations)
- CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia (30 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Gene
- Cancer
Multiple myeloma, Cancer research, Daratumumab, Immunotherapy and Bone marrow are his primary areas of study.
Many of his research projects under Multiple myeloma are closely connected to Cereblon with Cereblon, tying the diverse disciplines of science together.
His Cancer research study combines topics from a wide range of disciplines, such as Cell culture, Pomalidomide, Dexamethasone, Antigen and Monoclonal antibody.
His research in Antigen intersects with topics in Cytotoxic T cell and Cytokine secretion.
His research on Immunology and Antibody is centered around Daratumumab.
His Immunotherapy study which covers Elotuzumab that intersects with Autologous stem-cell transplantation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
